Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction.

Inghardt, Tord; Antonsson, Thomas; Ericsson, Cecilia; Hovdal, Daniel; Johannesson, Petra; Johansson, Carina; Jurva, Ulrik; Kajanus, Johan; Kull, Bengt; Michaëlsson, Erik; Pettersen, Anna; Sjögren, Tove; Sörensen, Henrik; Westerlund, Kristina; Lindstedt, Eva-Lotte

Inghardt, Tord; Antonsson, Thomas; Ericsson, Cecilia; Hovdal, Daniel; Johannesson, Petra; Johansson, Carina; Jurva, Ulrik; Kajanus, Johan; Kull, Bengt; Michaëlsson, Erik; Pettersen, Anna; Sjögren, Tove; Sörensen, Henrik; Westerlund, Kristina; Lindstedt, Eva-Lotte.

Affiliation

Inghardt T; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, 431 50 Mölndal, Gothenburg, Sweden.
Antonsson T; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, 431 50 Mölndal, Gothenburg, Sweden.
Ericsson C; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, 431 50 Mölndal, Gothenburg, Sweden.
Hovdal D; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, 431 50 Mölndal, Gothenburg, Sweden.
Johannesson P; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, 431 50 Mölndal, Gothenburg, Sweden.
Johansson C; Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, 431 50 Mölndal, Gothenburg, Sweden.
Jurva U; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, 431 50 Mölndal, Gothenburg, Sweden.
Kajanus J; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, 431 50 Mölndal, Gothenburg, Sweden.
Kull B; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, 431 50 Mölndal, Gothenburg, Sweden.
Michaëlsson E; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, 431 50 Mölndal, Gothenburg, Sweden.
Pettersen A; Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, 431 50 Mölndal, Gothenburg, Sweden.
Sjögren T; Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, 431 50 Mölndal, Gothenburg, Sweden.
Sörensen H; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, 431 50 Mölndal, Gothenburg, Sweden.
Westerlund K; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, 431 50 Mölndal, Gothenburg, Sweden.
Lindstedt EL; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, 431 50 Mölndal, Gothenburg, Sweden.

J Med Chem ; 65(17): 11485-11496, 2022 09 08.

Article de En | MEDLINE | ID: mdl-36005476

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Défaillance cardiaque Limites: Animals / Humans Langue: En Journal: J Med Chem Sujet du journal: QUIMICA Année: 2022 Type de document: Article Pays d'affiliation: Suède

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google